We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00760370
Recruitment Status : Completed
First Posted : September 26, 2008
Last Update Posted : December 7, 2011
Odense University Hospital
Information provided by (Responsible Party):
Vejle Hospital

Brief Summary:
The investigators major aim is to determine whether there is a difference in the retention of zoledronic acid in multiple myeloma patients, compared to patients with breast cancer metastasis to bone. In addition the investigators wish to analyze if the retention of zoledronic acid is correlated to the extent of bone resorption/formation, and if there is a tendency to changes in retention with sequential treatment.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Breast Cancer Drug: Zoledronic Acid Phase 2

Detailed Description:

The clinical benefit from treatment with bisphosphonates has been documented in a large number of clinical studies, and bisphosphonates are now widely used for treatment of pain and prevention of bone fractures or vertebral collapse for example in patients with cancer metastasis to bone or multiple myeloma.

Repeated intravenous administration of the more potent bisphosphonates (pamidronate and zoledronic acid) are often used for treatment of osteolytic disease caused by disseminated cancer or multiple myeloma, while the less potent oral bisphosphonates are often prescribed for treatment of benign osteoporosis. The recommended dose and time schedule for treatment with the more potent bisphosphonates is based on concerns of avoiding toxicity and at the same time obtaining maximal clinical benefit. Clinical studies in multiple myeloma and bone metastasis show significant activity of pamidronate (90 mg by iv infusion during 2-4 hours) or zoledronic acid (4 mg iv during 15 min) repeated every 4 weeks after a treatment period of 9 months and beyond, but the optimal duration of treatment is not known. This is a particular important issue since the use of potent bisphosphonates have been brought in connection with osteonecrosis.

In the present study we will compare the retention of Zometa with the effect on bone markers in patients with multiple myeloma or breast cancer with metastases to bone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone
Study Start Date : December 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Intervention Details:
  • Drug: Zoledronic Acid
    4 mg intravenous (iv), one treatment
    Other Name: Zometa

Primary Outcome Measures :
  1. Amount of Zometa retained in body [ Time Frame: 48 hrs ]

Secondary Outcome Measures :
  1. Changes in bone markers [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed with breast cancer and metastases to bone.
  • Patients diagnosed with multiple myeloma.
  • Patients who are scheduled to receive Zometa.
  • Post-menopausal women (at least 10 months since last period).
  • Newly diagnosed patients must have clear signs of osteolysis.

Exclusion Criteria:

  • Anti-estrogen treatment.
  • Patients given chemotherapy during or less than 7 days before study begin.
  • Patients receiving glucocorticoids less than 5 days prior to study begin or during the study period (14 days)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00760370

Layout table for location information
Odense University Hospital
Odense, Denmark, 5000
Vejle Hospital
Vejle, Denmark, 7100
Sponsors and Collaborators
Vejle Hospital
Odense University Hospital
Layout table for investigator information
Principal Investigator: Torben Plesner, MD, PhD Vejle Hospital
Layout table for additonal information
Responsible Party: Vejle Hospital
ClinicalTrials.gov Identifier: NCT00760370    
Other Study ID Numbers: 2007-003777-13
First Posted: September 26, 2008    Key Record Dates
Last Update Posted: December 7, 2011
Last Verified: December 2011
Keywords provided by Vejle Hospital:
bone marker
breast cancer
multiple myeloma
bone specific ALP
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Site
Breast Diseases
Skin Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Zoledronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs